Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1914 elderly unresectable stage III NSCLC chemoradiotherapy trial
jRCTs031200230Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel and durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Dec 2020; status: active, not recruiting.
02
Drugs
carboplatinpaclitaxeldurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031200230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200230.